Virally induced colorectal cancer drug resistance DOI
Zilungile L. Mkhize‐Kwitshana, Pragalathan Naidoo, Roxanne Pillay

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 383 - 424

Published: Nov. 8, 2024

Language: Английский

Exploiting innate immunity for cancer immunotherapy DOI Creative Commons
Ming Yi, Tianye Li,

Mengke Niu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Nov. 27, 2023

Abstract Immunotherapies have revolutionized the treatment paradigms of various types cancers. However, most these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory bispecific T cell engager and chimeric antigen receptor (CAR)-T cell. Although agents already achieved great success, only a tiny percentage patients could benefit from immunotherapies. Actually, immunotherapy efficacy is determined multiple components in tumor microenvironment beyond immunity. Cells innate arm system, such as macrophages, dendritic cells, myeloid-derived suppressor neutrophils, natural killer unconventional also participate cancer evasion surveillance. Considering that cornerstone antitumor response, utilizing immunity provides potential therapeutic options for control. Up to now, exploiting agonists stimulator interferon genes, CAR-macrophage -natural therapies, metabolic regulators, novel exhibited potent activities preclinical clinical studies. Here, we summarize latest insights into roles cells discuss advances arm-targeted strategies.

Language: Английский

Citations

92

Targeting cytokine and chemokine signaling pathways for cancer therapy DOI Creative Commons
Ming Yi, Tianye Li,

Mengke Niu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: July 22, 2024

Abstract Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles both normal physiology the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, growth factors like TGF-β, VEGF, EGF, can promote or inhibit growth, influence microenvironment, impact efficacy cancer treatments. Recent advances targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate system, progression, overcome resistance conventional therapies. In this review, we summarized current understanding implications cytokine chemokine signaling By exploring molecules biology response, highlighted development novel agents aimed at modulating combat The review elaborated on nature cytokines promoters suppressors tumorigenesis, depending context, discussed challenges opportunities presents for intervention. We also examined latest advancements targeted therapies, monoclonal antibodies, bispecific receptor inhibitors, fusion proteins, engineered variants, their metastasis, microenvironment. Additionally, evaluated potential combining therapies with other treatment modalities improve patient outcomes. Besides, focused ongoing research clinical trials that pivotal advancing our application cytokine- chemokine-targeted patients.

Language: Английский

Citations

72

Novel immune checkpoint targets: A promising therapy for cancer treatments DOI
Mohsina Patwekar, Nouroz Sehar,

Faheem Patwekar

et al.

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 126, P. 111186 - 111186

Published: Nov. 17, 2023

Language: Английский

Citations

25

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling DOI Creative Commons
Tianye Li,

Mengke Niu,

Jianwei Zhou

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: March 12, 2024

Abstract The programmed cell death 1 (PD-1) signaling pathway, a key player in immune checkpoint regulation, has become focal point cancer immunotherapy. In the context of cancer, upregulated PD-L1 on tumor cells can result T exhaustion and evasion, fostering progression. advent PD-1/PD-L1 inhibitor demonstrated clinical success by unleashing from exhaustion. Nevertheless, challenges such as resistance adverse effects have spurred exploration innovative strategies, with bispecific antibodies (BsAbs) emerging promising frontier. BsAbs offer multifaceted approach to immunotherapy simultaneously targeting other regulatory molecules. We focus recent advancements therapy particular emphasis development potential BsAbs, especially solid tumors. Various BsAb products PD-1 are discussed, highlighting their unique mechanisms action therapeutic potential. Noteworthy examples include anti-TGFβ × PD-L1, anti-CD47 anti-VEGF anti-4-1BB anti-LAG-3 anti-PD-1 CTLA-4 BsAbs. Besides, we summarize ongoing studies evaluating efficacy safety these agents. By unraveling intricacies microenvironment harnessing synergistic anti-PD-1/PD-L1 there exists elevate precision immunotherapy, ultimately enabling personalized treatment strategies tailored individual patient profiles.

Language: Английский

Citations

16

Immunotherapy for colorectal cancer: insight from inherited genetics DOI
Nijole P. Tjader, Amanda E. Toland

Trends in cancer, Journal Year: 2024, Volume and Issue: 10(5), P. 444 - 456

Published: Feb. 14, 2024

Language: Английский

Citations

10

Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer DOI
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Language: Английский

Citations

1

Immune checkpoint blockade in hematological malignancies: current state and future potential DOI Creative Commons

Prateek Pophali,

Juan Carlos Varela,

Jacalyn Rosenblatt

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 23, 2024

Malignant cells are known to evade immune surveillance by engaging checkpoints which negative regulators of the system. By restoring T-lymphocyte mediated anti-tumor effect, checkpoint inhibitors (ICI) have revolutionized treatment solid tumors but met rather modest success in hematological malignancies. Currently, only FDA approved indications for ICI therapy classic hodgkin lymphoma and primary mediastinal B cell lymphoma. Multiple clinical trials assessed alone combination with standard care treatments other lymphomas, plasma neoplasms myeloid were noted limited efficacy. These mostly focused on PD-1/PDL-1 CTLA-4 inhibitors. Recently, there has been an effort target like LAG-3, TIM-3, TIGIT along improving strategies inhibition. Drugs targeting macrophage checkpoint, CD47, also being tested. Long term safety efficacy data from these ongoing studies eagerly awaited. In this comprehensive review, we discuss mechanism inhibitors, key takeaways reported results completed therapies context

Language: Английский

Citations

8

Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration DOI Open Access
Xinru Li, Yawen Li, Halahati Tuerxun

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117298 - 117298

Published: Aug. 15, 2024

Immune checkpoint blocking (ICB), a tumor treatment based on the mechanism of T-cell activation, has shown high efficacy in clinical trials, but not all patients benefit from it. inhibitors (ICIs) do respond to cold tumors that lack effective infiltration well hot with sufficient infiltration. How convert an unresponsive into responsive is important topic cancer immunotherapy. Ferroptosis, newly discovered immunogenic cell death (ICD) form, great potential therapy. In process deeply understanding formation, it was found ferroptosis showed powerful immune-activating effect by improving infiltration, and combination ICB therapy significantly enhanced anti-tumor efficacy. This paper reviews complex relationship between T cells ferroptosis, as summarizes various mechanisms which enhances infiltration: reactivation reversal immunosuppressive microenvironment (TME), recent advances ICI targeted therapies, provides guidance for better tumors.

Language: Английский

Citations

5

The role of transforming growth factor-β (TGF-β) in the formation of exhausted CD8 + T cells DOI Creative Commons

Rong Ma,

Jinhan Sun, Yanyang Wang

et al.

Clinical and Experimental Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: June 17, 2024

Abstract CD8 + T cells exert a critical role in eliminating cancers and chronic infections, can provide long-term protective immunity. However, under the exposure of persistent antigen, differentiate into terminally exhausted lose ability immune surveillance disease clearance. New insights molecular mechanisms T-cell exhaustion suggest that it is potential way to improve efficacy immunotherapy by restoring function cells. Transforming growth factor- β (TGF- ) an important executor homeostasis tolerance, inhibiting expansion many components system. Recent studies have shown TGF- one drivers for development In this review, we summarized formation discussed ways target those ultimately enhance immunotherapy.

Language: Английский

Citations

4

Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer DOI Creative Commons
Pankaj Kumar Garg, Siddhika Pareek, Prakash Kulkarni

et al.

Biochemical Pharmacology, Journal Year: 2024, Volume and Issue: 231, P. 116646 - 116646

Published: Nov. 20, 2024

Language: Английский

Citations

4